The next generation of PPAR drugs: do we have the tools to find them?
about
Selected Extracts of Chinese Herbal Medicines: Their Effect on NF-κB, PPARα and PPARγ and the Respective Bioactive CompoundsMBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activationNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewPPARs and the cardiovascular systemDesign novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approachIdentification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validationIdentification of PPARgamma partial agonists of natural origin (II): in silico prediction in natural extracts with known antidiabetic activityMBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated ReceptorsAnti-Inflammatory and PPAR Transactivational Effects of Oleanane-Type Triterpenoid Saponins from the Roots of Pulsatilla koreanaPharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.Nutraceuticals as Ligands of PPARγGenomic DNA methylation changes in NYGGF4-overexpression 3T3-L1 adipocytes.Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.PPARs and the kidney in metabolic syndrome.Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities.The therapeutic potential of the adiponectin pathway.Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.Fat and bone interactions.Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity.Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation.Anti-Diabetic Effects of an Ethanol Extract of Cassia Abbreviata Stem Bark on Diabetic Rats and Possible Mechanism of Its Action: - Anti-diabetic Properties of Cassia abbreviata.Identification of a proliferator-activated receptor-γ antagonist for the treatment of type 2 diabetes mellitus.Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice.Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes.Peroxisome proliferator-activated receptor transactivational effects in HepG2 cells of cembranoids from the soft coral Lobophytum crassum Von Marenzeller.Prospective QSAR-Based Prediction Models with Pharmacophore Studies of Oxadiazole-Substituted α-Isopropoxy Phenylpropanoic Acids with Dual Activators of PPARα and PPARγ.Prospective QSAR-based prediction models with pharmacophore studies of oxadiazole-substituted α-isopropoxy phenylpropanoic acids on with dual activators of PPARα and PPARγPPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a homeIdebenone and coenzyme Q10are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases
P2860
Q21285130-CA033BAF-7775-4612-A8C9-710089FE2861Q21342745-A526DCDA-EAD8-4C0F-89D9-0EB08B56BE1DQ24561401-A278B493-0CBA-4748-92EC-845FD2F3AA29Q24642728-6C4A5615-8E16-4813-B236-B6348A392C06Q28484141-DC122A1B-9530-47B9-AD97-849735C0B5D7Q28485402-8D984E9F-0622-421E-9053-F222F56E57DAQ28486003-6ACC7013-5C98-4415-ACDA-AF1CDD2F6CBFQ33642155-2E0059FF-D96D-4C7C-A2AE-21BF04553146Q33960919-E2B2EECD-CDA3-4247-B605-9A4B5B34E3C9Q34039797-3304CE68-1742-4D35-9BA0-AEC40EA0D54FQ34628781-AFA88005-9C4F-4B7A-8519-2FC10F93353BQ35237706-5238C934-5E95-437B-A48A-6480F3A482E9Q35395528-0EDBBC93-7594-4A55-9C35-92D7C773BD7BQ35636191-6917BB6B-9076-4DB6-AAC9-31B5D8D94EB2Q35842216-E7AABEAD-821C-4EF2-9EDD-0D2AA9A2C81BQ36072211-4C2DC448-EC92-4050-AA49-21073A816613Q36538260-665F0E15-52B0-4F32-9348-B62154E82A73Q36724770-13AC3ED6-69EB-4189-8BB9-84A8AAEAE36BQ37072216-B8CC8E7F-118F-4093-BF98-B93AB998A264Q37137719-46F71B00-4F33-458B-B4FE-7BC6CCAFE0A2Q37952283-F78C46CA-0C98-4B76-A547-184EBC26133DQ38128537-F9C99875-FACD-4D65-8C96-FB3A41B50955Q38193721-3DBFE4BC-F134-4DCA-BC5B-4330455DBDC5Q38320967-BD16429E-25F1-4AC9-A9BB-8CD0E04526FAQ39018398-CB3D4F79-0EAC-4063-A0E6-18B406FB8A26Q40488248-6A8C4F2E-0FAD-4BE5-9965-00E8B8AD775CQ42036117-109562DC-8040-4062-871F-ABDD04BCFD45Q42812796-D40E659B-49EF-46F7-9720-DBF6CA5A660BQ47111177-FA3688AA-CCBB-4C33-A27B-6FE3B93DCEFFQ50673379-2525F91B-AB9F-4613-898A-E27A9943EBC7Q50882338-DBB966B6-8DB8-4C57-9B24-CEB25229E949Q51044220-FC134AFA-FF83-40F1-877C-FF8A6B03C80CQ55919570-BF41A6C2-40C2-47A3-BF4C-D418E35C7D53Q57269164-60E7B56C-DE76-4665-9A34-B6121F232F3F
P2860
The next generation of PPAR drugs: do we have the tools to find them?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The next generation of PPAR drugs: do we have the tools to find them?
@en
type
label
The next generation of PPAR drugs: do we have the tools to find them?
@en
prefLabel
The next generation of PPAR drugs: do we have the tools to find them?
@en
P1476
The next generation of PPAR drugs: do we have the tools to find them?
@en
P2093
Barry G Shearer
P304
P356
10.1016/J.BBALIP.2007.05.005
P407
P577
2007-06-02T00:00:00Z